SCHEMBL14157595

SCHEMBL14157595

NC(=O)C12CC3CC(C1)C(NC(=O)c1cccc(Cl)n1)C(C3)C2

nearest known ligand 0.52

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 20/20 0.52
▸ HSD11B2 P80365 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15706725 1.00 HSD11B1 (0.52) HSD11B1HSD11B2
SCHEMBL14157736 0.87 HSD11B1 (0.52) HSD11B1HSD11B2
SCHEMBL15706767 0.87 HSD11B1 (0.52) HSD11B1HSD11B2
SCHEMBL15706762 0.86 HSD11B1 (0.52) HSD11B1HSD11B2
SCHEMBL14157705 0.86 HSD11B1 (0.52) HSD11B1HSD11B2
SCHEMBL27941142 0.86 HSD11B1 (0.48) HSD11B1HSD11B2
SCHEMBL15706751 0.84 RAB9A (0.56) HSD11B1HSD11B2
SCHEMBL14157699 0.84 RAB9A (0.56) HSD11B1HSD11B2
SCHEMBL15706758 0.84 HSD11B1 (0.49) HSD11B1HSD11B2
SCHEMBL14157732 0.84 HSD11B1 (0.53) HSD11B1HSD11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103649066-B 5-carbamyl-diamantane (obsolete)-2-yl amide derivatives, its pharmaceutically acceptable salt and preparation method thereof 爱思开生物制药株式会社 2016-08-17 — — CN disclosed
EP-2699560-B1 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2016-04-20 — — EP disclosed
US-9233957-B2 5-carbamoyl-adamantan-2-yl amide derivatives, pharmaceutically acceptable salts thereof and preparation process thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2016-01-12 — — US disclosed
US-20140128427-A1 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-05-08 — — US disclosed
EP-2699560-A2 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF SK Biopharmaceuticals Co., Ltd. (KR) 2014-02-26 — — EP disclosed
WO-2012169863-A2 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2012-12-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140128427-A1 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF HSD3B1, HSD11B1, HSD3B2 HSD11B1 2/4885HSD11B2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback